Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma

JCO Precis Oncol. 2018:2018:PO.18.00135. doi: 10.1200/PO.18.00135. Epub 2018 Nov 8.

Authors

Elizabeth H Stover¹, Colleen Feltmate¹, Ross S Berkowitz¹, Neal I Lindeman¹, Ursula A Matulonis¹, Panagiotis A Konstantinopoulos¹

Affiliation

¹ Elizabeth H. Stover, Ursula A. Matulonis, and Panagiotis A. Konstantinopoulos, Dana-Farber Cancer Institute, Harvard Medical School; and Colleen Feltmate, Ross S. Berkowitz, and Neal I. Lindeman, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

No abstract available

Grants and funding

KL2 TR001100/TR/NCATS NIH HHS/United States